Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myofibroblastic tumours: an update.

C D Fletcher1

  • 1Department of Pathology, Harvard Medical School, Boston, MA, USA.

Verhandlungen Der Deutschen Gesellschaft Fur Pathologie
|March 30, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unique case of a <i>GLI1</i> amplified biphasic mesenchymal tumor of the orbit.

Orbit (Amsterdam, Netherlands)·2023
Same author

A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer.

British journal of cancer·2012
Same author

Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.

Oncogene·2009
Same author

Gastrointestinal stromal tumours: an update.

Sarcoma·2008
Same author

Problems in grading soft tissue sarcomas.

American journal of clinical pathology·2002
Same author

The role of megestrol acetate as an alternative to conventional hormone replacement therapy.

Climacteric : the journal of the International Menopause Society·2002
Same journal

[The PEA-15 protein induces resistance against glucose deprivation-induced cell death via the ERK/MAP kinase pathway].

Verhandlungen der Deutschen Gesellschaft fur Pathologie·2008
Same journal

[Methylation status of LINE-1 sequences in patients with MDS or secondary AML].

Verhandlungen der Deutschen Gesellschaft fur Pathologie·2008
Same journal

[Heat shock protein 90 alpha und beta are overexpressed in multiple myeloma cells and critically contribute to survival].

Verhandlungen der Deutschen Gesellschaft fur Pathologie·2008
Same journal

[Gastrin cell hyperplasia associated with duodenal MEN1-related gastrinomas: histopathology and genetics].

Verhandlungen der Deutschen Gesellschaft fur Pathologie·2008
Same journal

Artificial intelligence and bladder cancer arrays.

Verhandlungen der Deutschen Gesellschaft fur Pathologie·2008
Same journal

[Mapping of a deletion interval on 8p21-22 in prostate cancer by gene dosage PCR].

Verhandlungen der Deutschen Gesellschaft fur Pathologie·2008
See all related articles

The myofibroblast, a cell type defined less than 30 years ago, presents challenges in classification. Despite debate, numerous soft tissue tumors exhibit myofibroblastic features, necessitating a clear definition for accurate diagnosis.

Area of Science:

  • Pathology
  • Cell Biology
  • Oncology

Background:

  • The myofibroblast is a recently defined cell type (less than 30 years ago) with debated morphological and phenotypic characteristics.
  • Its intermediate features between fibroblasts and smooth muscle cells lead some to question the existence of true myofibroblastic tumors.
  • Despite definitional challenges, many soft tissue tumors display clear myofibroblastic features.

Purpose of the Study:

  • To review the classification and diagnostic challenges of myofibroblastic tumors.
  • To highlight the spectrum of lesions exhibiting myofibroblastic differentiation.
  • To advocate for a standardized definition of the myofibroblast in tumor pathology.

Main Methods:

  • Review of literature on myofibroblast biology and tumor pathology.

Related Experiment Videos

  • Categorization of soft tissue tumors with myofibroblastic features.
  • Analysis of diagnostic criteria and histogenetic concepts.

    • Main Results:

    • Myofibroblastic features are observed in diverse soft tissue lesions, including reactive fasciitis-like lesions, benign tumors (e.g., myofibroblastoma), aggressive fibromatoses, and sarcomas.
    • Specific examples include infantile fibrosarcoma, inflammatory myofibroblastic tumor, and some high-grade pleomorphic sarcomas (formerly MFH).
    • The spectrum ranges from low-grade to high-grade malignancies with myofibroblastic differentiation.

    Conclusions:

    • The existence of myofibroblastic tumors is supported by extensive pathological evidence, despite ongoing definitional debates.
    • Accurate diagnosis relies on recognizing phenotypic features, even with evolving histogenetic concepts.
    • A reproducible and agreed-upon definition of the myofibroblast is crucial for advancing tumor pathology.